Skip to main content
Livermore
Livermore
ZHEN

Knott David M Jr

SEC CIK
0001892770
Latest filing
Aug 12, 2026

The latest 13F from Knott David M Jr covers Q2 2026 (filed Aug 12, 2026): 84 long positions worth $189.2M. The top 10 holdings make up 62.8% of the portfolio, and the largest is Alphabet Inc. (GOOG) at 17.1%. Livermore has 19 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
10
Est. +$6.92M
Added
17
Est. +$4.18M
Reduced
4
Est. −$2.40M
Sold out
11
Est. −$10.4M

Top 5 holdings

Share of this quarter's portfolio value

  1. GOOGAlphabet Inc.
    17.1%$32.3MHistory
  2. APOApollo Global Management, Inc.
    14.1%$26.6MHistory
  3. SNDXSyndax Pharmaceuticals Inc
    5.1%$9.56MHistory
  4. XERSXeris Biopharma Holdings, Inc.
    4.4%$8.40MHistory
  5. TVTXTravere Therapeutics, Inc.
    4.4%$8.37MHistory

Share of portfolio

Top 5 holdings and the other 79 positions, by share of portfolio value

  1. GOOG17.1%
  2. APO14.1%
  3. SNDX5.1%
  4. XERS4.4%
  5. TVTX4.4%
  6. Other 79 positions54.9%

Biggest buys

New and added positions, by estimated amount bought

  1. CLSTCatalyst Bancorp, Inc.
    +$3.58MNewHistory
  2. SPRBSpruce Biosciences, Inc.
    +$1.08MNewHistory
  3. CGEMCullinan Therapeutics, Inc.
    +$819.1KAddedHistory
  4. MDGLMadrigal Pharmaceuticals, Inc.
    +$537.0KAddedHistory
  5. INSMINSMED Inc
    +$453.5KNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. TVTXTravere Therapeutics, Inc.
    +1.94 pp2.5% → 4.4%History
  2. CLSTCatalyst Bancorp, Inc.
    +1.89 pp0.0% → 1.9%History
  3. ALKSAlkermes plc.
    +0.85 pp2.5% → 3.4%History
  4. SPRBSpruce Biosciences, Inc.
    +0.57 pp0.0% → 0.6%History
  5. CGEMCullinan Therapeutics, Inc.
    +0.46 pp0.2% → 0.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CPRXCatalyst Pharmaceuticals, Inc.
    −$2.97MSold outHistory
  2. ACLXArcellx, Inc.
    −$2.23MSold outHistory
  3. CYTKCytokinetics Inc
    −$1.56MSold outHistory
  4. CNTACentessa Pharmaceuticals plc
    −$1.55MSold outHistory
  5. TGTXTG Therapeutics, Inc.
    −$1.27MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CPRXCatalyst Pharmaceuticals, Inc.
    −1.77 pp1.8% → 0.0%History
  2. ACLXArcellx, Inc.
    −1.33 pp1.3% → 0.0%History
  3. CYTKCytokinetics Inc
    −0.93 pp0.9% → 0.0%History
  4. CNTACentessa Pharmaceuticals plc
    −0.92 pp0.9% → 0.0%History
  5. BMYBristol Myers Squibb Co
    −0.43 pp0.5% → 0.1%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$189.2M
+$21.1M (+12.6%) vs. prior quarter
Positions
84
−1 vs. prior quarter
Top 10 concentration
62.8%
Top 10 as share of value
Turnover
6.2%
Q2 2026, one quarter
Average holding period
10.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $291.4M (Q1 2022)

Q4 2021: $264.5MQ1 2022: $291.4MQ2 2022: $215.5MQ3 2022: $213.7MQ4 2022: $231.2MQ1 2023: $237.9MQ2 2023: $236.4MQ3 2023: $253.6MQ4 2023: $261.6MQ1 2024: $282.8MQ2 2024: $250.6MQ3 2024: $250.8MQ4 2024: $276.5MQ1 2025: $212.0MQ2 2025: $220.6MQ3 2025: $238.7MQ4 2025: $215.9MQ1 2026: $168.0MQ2 2026: $189.2M
Q4 2021Q2 2026
13F filings of Knott David M Jr by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 12, 202684$189.2MGOOGAPOSNDXvs. Q1 2026SEC
Q1 2026May 14, 202685$168.0MGOOGAPOSNDXvs. Q4 2025SEC
Q4 2025Feb 12, 202687$215.9MCLMTAPOGOOGvs. Q3 2025SEC
Q3 2025Nov 12, 202587$238.7MCLMTAPOGOOGvs. Q2 2025SEC
Q2 2025Aug 11, 202585$220.6MCLMTAPOJanus Detroit STR Trvs. Q1 2025SEC
Q1 2025May 12, 202584$212.0MCLMTAPOJanus Detroit STR Trvs. Q4 2024SEC
Q4 2024Feb 12, 202589$276.5MCLMTAPOJanus Detroit STR Trvs. Q3 2024SEC
Q3 2024Nov 13, 202492$250.8MCLMTAPOGOOGvs. Q2 2024SEC
Q2 2024Aug 12, 202499$250.6MCLMTAPOGOOGvs. Q1 2024SEC
Q1 2024May 14, 2024106$282.8MCLMTAPOSeries Portfolios Trvs. Q4 2023SEC
Q4 2023Feb 13, 2024113$261.6MCLMTAPOFTAIvs. Q3 2023SEC
Q3 2023Nov 13, 2023132$253.6MCLMTAPOFTAIvs. Q2 2023SEC
Q2 2023Aug 11, 2023149$236.4MCLMTAPOGOOGvs. Q1 2023SEC
Q1 2023May 11, 2023150$237.9MCLMTAPODCGOvs. Q4 2022SEC
Q4 2022Feb 13, 2023174$231.2MCLMTAPOFBRTvs. Q3 2022SEC
Q3 2022Nov 10, 2022184$213.7MCLMTDCGOGOOGvs. Q2 2022SEC
Q2 2022Aug 11, 2022188$215.5MCLMTGOOGFBRTvs. Q1 2022SEC
Q1 2022May 16, 2022140$291.4MCLMTGOOGAPOvs. Q4 2021SEC
Q4 2021Feb 11, 2022132$264.5MCLMTAPOGOOG–SEC

13D and 13G filings

Companies where Knott David M Jr reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Knott David M Jr does not currently report owning 5% or more of any company.

Latest filings

5 filings on file made by Knott David M Jr or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Knott David M Jr
CompanyFiled (ET)FormStakeChangeEvent dateFiling
CLMTCalumet, Inc.Feb 12, 20252:15 PM ET13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
MDWTMidwest Holding Inc.Dec 22, 202313D/AOld format–––SEC
MDWTMidwest Holding Inc.Aug 18, 202213D/AOld format–––SEC
MDWTMidwest Holding Inc.May 20, 202213DOld format–New–SEC
CLMTCalumet, Inc.Nov 8, 202113GOld format–New–SEC